Long-term Survival Following Photodynamic Therapy for Glioma Depending on MGMT - European Medical Journal

Continue

Long-term Survival Following Photodynamic Therapy for Glioma Depending on MGMT

1 Mins
Oncology
EMJ Oncology 8.1 2020 Feature Image
Authors:
Rynda Artemii Yurievich,1 Rostovtsev Dmitrii Michailovich,1 Olyushin Victor Emelijanovich,1 Zabrodskaya Yliay Michaiylovna2

1. Department of Surgery for Brain and Spinal Cord Tumors, A.L. Polenov Russian Neurosurgical Research Institute, V.A. Almazov National Medical Research Centre of the Ministry of Health of Russia, St. Petersburg, Russia
2. Department of Pathomorphology, A.L. Polenov Russian Neurosurgical Research Institute, V.A. Almazov National Medical Research Centre of the Ministry of Health of Russia, St. Petersburg, Russia
*Correspondence to [email protected]

Disclosure:

The authors have declared no conflicts of interest.

Acknowledgements:

This work was supported by the A.L. Polenov Russian Neurosurgical Research Institute, V.A. Almazov National Medical Research Centre of the Ministry of Health of Russia, St. Petersburg, Russia.

Citation:
EMJ Oncol. ;8[1]:51-52. Abstract Review No. AR5.
Keywords:
Glioma, malignant, MGMT, neuro-oncology, photodynamic therapy (PDT), survival.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

BACKGROUND AND AIMS

The gross total resection of a glial tumour is the aim of complex treatment and gives greater efficiency of the subsequent treatment stages, defining patients’ longevity. The impossibility of radical surgical treatment, short period of recurrency, and average longevity dictates the search for new treatment methods. Intraoperative photodynamic therapy (PDT) may lead to an increase in totality of tumour resection.1-4

The aim of the study was to increase the survival rate and duration of the relapse-free period in patients with malignant brain gliomas by using PDT as part of complex treatment.5-7

MATERIALS AND METHODS

The study included patients with glial brain tumours of supratentorial localisation with a high degree of malignancy (Grade IV glioblastoma) undergoing treatment at the Russian Neurosurgical Research Institute. The study group included 50 patients and there were 50 patients in the control group. Patients in the study group were injected intravenously 1.5 hours before the operation with a photosensitiser of the chlorine e6 group (2nd generation). After resection of the tumours, a PDT session was performed using a Latus-2.5 laser (Lotus Laser Systems, Basildon, UK) as a radiation source. The average dose was 180 J/cm2. In the postoperative period, patients in both groups received adjuvant therapy (chemotherapy and radiation therapy).8,9 Long-term results (inter-recurrence period and overall survival) were evaluated depending on the results of immunohistochemical studies (the presence of IDH mutation and MGMT).

RESULTS

The median survival for patients with Grade IV gliomas (MGMT+) using PDT was 23.3±4.1 months; in the control group (without PDT) the median survival was 16.5±3.3 months (p=0.0002). The median survival for patients with Grade IV gliomas (MGMT-) using PDT was 18.2±3.5 months; in the control group (without PDT) this was 11.2±2.4 months (p=0.0001). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT+) was 13.5±2.3 months in the study group and 9.1±1.4 months in the control group (p=0.0003). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT-) was 10.1±2.2 months in the study group and 7.0±1.1 months in the control group (p=0.0001).

CONCLUSION

PDT increased the median of the inter-relapse period and life expectancy in patients with malignant gliomas. In patients expressing MGMT, the magnitude of the inter-relapse period and life expectancy was significantly higher in the group receiving PDT.

References
Hirschberg H et al. Photodynamic therapy mediated immune therapy of brain tumors. Neuroinflamm. 2018;(5)27:1-16. Mahmoudi K et al. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol. 2019;141(3):595-607. Fisher CJ et al. ALA-PpIX mediated photodynamic therapy of malignant gliomas augmented by hypothermia. PLoS ONE. 2017;(12)7:e0181654. Shimizu K et al. Intraoperative photodynamic diagnosis using talaporfin sodium simultaneously applied for photodynamic therapy against malignant glioma: a prospective clinical study. Front Neurol. 2018;9:24. Dupont C et al.; SPIE. Intraoperative photodynamic treatment for high-grade gliomas. 2017. Available at: https://www.spiedigitallibrary.org/conference- proceedings-of-spie/10047/100470N/Intraoperative-photodynamic-treatment-for-high-grade-gliomas/10.1117/12.2251351.short. Last accessed: 14 October 2020. Tzerkovsky DA et al. [The role of photodynamic therapy in the treatment of primary, recurrent and metastatic malignant brain tumors]. Biomedical Photonics. 2018;(7)2:37-49. (In Russian). Yuan SX et al. Underlying mechanism of the photodynamic activity of hematoporphyrin‑induced apoptosis in U87 glioma cells. Int J Mol Med. 2018;41:22-96. Rynda A et al. Therapeutic pathomorphosis in malignant glioma tissues after photodynamic therapy with сhlorin e6 (reports of two clinical cases). Biomedical Photonics. 2020;9(2):45-54. Rynda A et al. P14.22 Long-term survival of treatment of HGG using PDT. Neuro Oncol. 2019;21(Suppl 3):iii71.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given